Recent Updates
Recently added Catalysts

Stargardt Disease: two biotech companies racing to a treatment

OphthalmologyConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$3.7Buniverse median $1.20B
Allocated capital$3.6B$7.3B competing
Phase 3 or filed02 mid, 0 early
Pure plays0this indication only
Capital rank53/299crowding rank 74

Stargardt Disease is a two-horse race: Belite Bio (BLTE, $6.9B) against Ocugen (OCGN, $458M).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $3.6B of allocated capital sits on the pair.

BLTE alone accounts for 94% of the $7.3B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$3.6B of allocated capital sits in Stargardt Disease, ranking it 53rd of 299 indications by the money committed to it.

Companies developing drugs for Stargardt Disease 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
BLTEBelite BioTinlarebantPhase 21$6.9BNo2 12 Feb 2027
OCGNOcugenOCU410STPhase 21$458MNo3 24 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. BLTE holds 94% of the $7.3B competing in this indication.

Why Stargardt Disease is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Stargardt Disease has 2 competitors and a median of $3.7B.

Ophthalmology

Ophthalmology holds $17.0B of the map's capital, 2.5% of the total, spread across 9 indications and 13 companies. 6 of those indications have more than one company competing.

See every Ophthalmology indication on the map

Related indications in Ophthalmology

Wet Age-related Macular Degeneration4 companies · $3.5B · median $1.5BConcentrated betGeographic Atrophy3 companies · $4.0B · median $918MOrphan cornerDry Eye Disease3 companies · $2.0B · median $706MOrphan cornerDiabetic Macular Edema4 companies · $1.3B · median $613MOrphan cornerHereditary Transthyretin Amyloidosis1 company · $1.1B · median $9.7BUncontestedMacular Edema1 company · $758M · median $2.3BUncontestedLeber Congenital Amaurosis2 companies · $600M · median $300MOrphan cornerX-Linked Retinitis Pigmentosa1 company · $192M · median $768MUncontested

Stargardt Disease pipeline questions

Which biotech companies are developing drugs for Stargardt Disease?

Belite Bio (BLTE, Tinlarebant, Phase 2); Ocugen (OCGN, OCU410ST, Phase 2). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Stargardt Disease.

How advanced is the Stargardt Disease pipeline?

Of the 2 clinical-stage programmes in Stargardt Disease, 0 are in Phase 3 or filed, 2 are in mid-stage development and 0 are in early-stage development.

Which company leads the Stargardt Disease field?

BLTE is the largest developer in Stargardt Disease, holding 94% of the $7.3B of market capitalisation competing in the indication. The median competitor is worth $3.7B.

When is the next Stargardt Disease catalyst?

The next dated catalyst in Stargardt Disease is OCGN on 24 Sep 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map